MedTrace Logo

A Study of LY2140023 in Healthy Participants

NCT01659177 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2021-08-23

No results posted yet for this study

Summary

The study will evaluate the effect of food on absorption of LY2140023 in blood. This study involves a single dose of 80 mg LY2140023 taken as a tablet by mouth on 2 occasions, once on an empty stomach and once after eating breakfast. There is a minimum 3 day washout between doses. This study will last approximately 16 days not including screening. Screening is required within 30 days prior to the start of the study.

Conditions

  • Healthy Participants

Interventions

DRUG

LY2140023

Administered orally

Sponsors & Collaborators

  • Denovo Biopharma LLC

    lead INDUSTRY

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01659177 on ClinicalTrials.gov